New insurer partnerships signal next steps for buzzy biotech EQRx

Table of Contents

EQRx — the buzzy biotech company with a lofty mission of making far less expensive look-alike versions of blockbuster drugs — is finally starting to sign deals with insurance companies, a key step toward launching drugs that could shake up the market for medicines. But the deals are light on details, raising questions about just how meaningful that shake-up might eventually be.

The company’s approach to developing drugs relies on “fast followers” — that is, drugs that are extremely similar to approved drugs that can be brought to market more quickly and cheaply than a product that’s breaking new ground. EQRx’s first two drugs for non-small cell lung cancer — aumolertinib and sugemalimab — are approved and pending approval in China, respectively.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

send message
Hello,
Iam Guest Posting Services
I Have 2000 sites
Status : Indexed All
Good DA : 20-60
Different Niche | Category
Drip Feed Allowed
I can instant publish
ASAP


My Services :

1. I will do your orders maximum of 1x24 hours, if at the time I'm online, I will do a maximum of 1 hour and the process is
completed.
2. If any of your orders are not completed a maximum of 1x24 hours, you do not have to pay me, or free.
3. For the weekend, I usually online, that weekend when I'm not online, it means I'm working Monday.
4. For the payment, maximum payed one day after published live link.
5. Payment via PayPal account.

If you interesting, please reply

Thank You

Regards,

IWAN